Breaking News Bar

Business News and Information

Emerging Healthcare Signs Option for New Diagnostic Test

Emerging Healthcare Solutions, Inc. (PinkSheets:EHSI) is pleased to announce the execution of an exclusive option agreement with ThromboVision, Inc. ThromboVision, a Houston-based healthcare diagnostics company committed to enabling people to lead longer and healthier lives, has developed and patented T-Guide®, a new cutting-edge diagnostic test to assist medical professionals with the treatment of heart disease.

Over 50 million Americans take aspirin and Plavix® to prevent heart attacks and strokes. Up to 30% of these patients may not respond to their treatment, leaving up to 15 million patients unprotected. ThromboVision’s T-Guide® responds to this need by providing a simple, inexpensive diagnostic test that can show a patient’s level of platelet stickiness, and their responsiveness to their prescribed treatments.

“We are excited about the opportunity to work with Emerging Healthcare Solutions to bring this important medical technology to cardiac patients worldwide,” said Dr. Edward Teitel, President of ThromboVision, Inc.

Thrombovision T-Guide® could save thousands of lives by quickly helping healthcare professionals personalize their patients’ anti-platelet treatment to help decrease the chances of a patient suffering a recurred heart attack or stroke. The ThromboVision T-Guide® test provides near instantaneous information as to the effectiveness of treatments.

The option agreement gives the companies a mutual due diligence review period prior to completing an investment and profit sharing agreement. The emphasis in future health care will be on cost control while maintaining quality care from physicians.

The largest players in the Dow Jones U.S. Healthcare Sector Index are Johnson & Johnson, (NYSE: JNJ), Pfizer, Inc. (NYSE: PFE), and Merck & Co. (NYSE: MRK).

About ThromboVision, Inc.

ThromboVision, Inc. is an in-vitro diagnostics company committed to enabling people to lead longer and healthier lives. ThromboVision provides easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis and treatment. The company’s products will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk factors, especially those related to platelet function and anti-platelet drug therapy.

For more information please visit http://www.thrombovision.com.

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. is a company dedicated to providing guidance to participants in the healthcare industry. Our primary goal is to give you a roadmap showing how to realize enormous profits from the changes occurring right now in the healthcare industry. Our common stock is traded under the symbol EHSI.

For more information, visit http://www.emerginghealthcaresolutionsinc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts:

Emerging Healthcare Solutions, Inc.
Kathleen Delaney, 713-821-1486
or
ThromboVision, Inc.
Edward R. Teitel, MD, 713-491-4449

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear